Seto A H, Dunlap D S
Medical University of South Carolina, Charleston 29425, USA.
Ann Pharmacother. 1996 Jul-Aug;30(7-8):868-70. doi: 10.1177/106002809603000728.
Tranexamic acid has the potential to be a pharmacologic adjunct for the prophylaxis of hemorrhagic complications occurring in the oncology population. The studies and cases reviewed here suggest that tranexamic acid administration may be a therapeutic option for bleeding prophylaxis in APL where enhanced fibrinolysis accompanies the disease state. Because of the lack of a control in these reports, and the small sample size, it is not possible to extrapolate these conclusions regarding the efficacy of tranexamic acid in preventing hemorrhage in the larger thrombocytopenic oncology population. However, these reports concluded that its administration is safe, with few adverse effects and no thromboembolic events noted. A large, well-designed, controlled clinical trial is needed before a recommendation for the routine use of tranexamic acid in the oncology population can be established.
氨甲环酸有可能作为一种药理学辅助药物，用于预防肿瘤患者出现的出血并发症。此处回顾的研究和病例表明，对于伴有增强纤维蛋白溶解的急性早幼粒细胞白血病（APL）患者，给予氨甲环酸可能是预防出血的一种治疗选择。由于这些报告缺乏对照且样本量小，无法将这些关于氨甲环酸预防较大血小板减少肿瘤患者出血疗效的结论外推。然而，这些报告得出结论，其应用是安全的，不良反应少，未观察到血栓栓塞事件。在能够推荐在肿瘤患者中常规使用氨甲环酸之前，需要进行一项大型、设计良好的对照临床试验。
